Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.
Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Evidence: Global Initiative for Asthma (GINA) 2025 · sources last checked 2026-08-20

Guideline updates
First published2026-07-02GINA 2025CTS 2021NICE/BTS/SIGN 2024

Built on the guideline editions listed above and published after physician review.

Reviewed and approved by the clinic physician · 2026-07-02.

This history lists guideline editions this tool follows and how updates changed its suggestions. It is not medical advice — always discuss decisions with your clinician.

Asthma inhaler selector

Choose the guideline lens (GINA / CTS / NICE-BTS-SIGN), enter the patient’s control and current treatment — get the reliever strategy and the recommended inhaler step (all now agree: never a SABA-only reliever), with each guideline’s year shown. For ages ≥12.

Guideline lens

Age bandchoose one

This tool is for ≥12; 6–11 and <6 use different pediatric ladders

Current treatmentchoose one

Symptom controlchoose one

Daytime symptoms, night waking, reliever use, activity limitation

Exacerbationschoose one

Current relieverchoose one

Device considerations

Reliever strategy

ICS-formoterol (AIR/MART) — a SABA-only reliever is no longer recommended at any step.

Recommended regimen

As-needed ICS-formoterol (AIR)

maintain and review; consider stepping down if stable ≥3 months

Notes

  • • Across GINA, CTS and NICE/BTS/SIGN: do NOT treat with a SABA-only reliever — an ICS-containing reliever (ICS-formoterol) is preferred at every step.
  • • GINA 2025 keeps two tracks: Track 1 (ICS-formoterol reliever, preferred) and Track 2 (daily controller + a separate reliever) when Track 1 isn't feasible.

Suggested drug classesPer GINA 2025.

Enter current treatment and symptom control to begin.

Switch the guideline lens to compare GINA’s two-track approach, CTS’s conservative mild-asthma stance, and NICE/BTS/SIGN’s single AIR/MART pathway.

Guidelines

References

  1. [1]Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2025 (two-track; ICS-formoterol reliever preferred over SABA-only). link
  2. [2]Canadian Thoracic Society. 2021 asthma guideline update (mild-asthma focused; PRN budesonide-formoterol option for ≥12). link
  3. [3]NICE/BTS/SIGN. NG245 — Asthma: diagnosis, monitoring and chronic asthma management, 2024 (single AIR/MART pathway; no SABA-only reliever). link